Full Press Release Details
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
June 23, 2026
NXL Positive Sentiment Score: 75/100
Discover Nexalin’s Neurostimulation Device Targeting Mental Health Disorders
Key Takeaway: Nexalin Technology announced that the investigator of its Brazilian clinical trial received the Young Researcher Award at BRAIN 2026. This recognition highlights the research evaluating the company's proprietary DIFS™ platform, which targets mental health disorders. The award underscores the potential significance of Nexalin's neurostimulation device in the field.
Price reaction · baseline $1.24 (2024-07-26 close) · hit pre-market · clean, no other NXL news in the window
day 0 close
-4%
Market Sentiment Analysis
POSITIVE FACTORS
- Nexalin's device targets mental health disorders.
- Recognition of research at a prestigious event.
- Potential for significant impact on mental health treatment.
Frequently Asked Questions
What award did Nexalin's researcher receive?
The researcher received the Young Researcher Award at BRAIN 2026.
What does Nexalin's DIFS™ platform target?
Nexalin's DIFS™ platform targets mental health disorders.
Where was the clinical trial conducted?
The clinical trial was conducted in Brazil.
What is the significance of the BRAIN 2026 event?
BRAIN 2026 is a prestigious event recognizing research in neuroscience.